<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491829</url>
  </required_header>
  <id_info>
    <org_study_id>511.77</org_study_id>
    <nct_id>NCT00491829</nct_id>
  </id_info>
  <brief_title>Flibanserin Versus Placebo in Premenopausal Women With HSDD</brief_title>
  <official_title>A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sprout Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sprout Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month
      treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women.

      To evaluate safety and tolerability of flibanserin in such patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary.</measure>
    <time_frame>baseline to 24 weeks</time_frame>
    <description>To obtain information on satisfying sexual events (SSEs), a small personal handheld electronic device was to be used by the patients to record such information daily (eDiary). An SSE was recorded when a patient answered &quot;yes&quot; to the eDiary question: &quot;Was the event satisfying for you?&quot;</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">945</enrollment>
  <condition>Sexual Dysfunctions, Psychological</condition>
  <arm_group>
    <arm_group_label>flibanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg qhs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flibanserin 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg qhs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo qhs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg qhs</intervention_name>
    <description>flibanserin 50 mg</description>
    <arm_group_label>flibanserin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg</intervention_name>
    <description>flibanserin 100mg</description>
    <arm_group_label>flibanserin 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women who are 18 years of age and older at the Screen Visit.

          2. Premenopausal women per the Stages of Reproductive Aging Workshop (STRAW) criteria
             with the primary diagnosis of HSDD, generalized acquired type, according to DSM IV-TR
             criteria. The current episode must be at least 24 weeks in duration by the Baseline
             Visit. Secondary Female Sexual Arousal Disorder and/or Female Orgasmic Disorder are
             allowed. This inclusion criterion is met only if the HSDD commenced prior to Female
             Sexual Arousal Disorder and/or Female Orgasmic Disorder and the HSDD is of more
             importance to the patient, in the investigator judgement

          3. A score of 15 or higher on the Female Sexual Distress Scale-Revised (FSDS-R)©
             (R04-1068) at the Screen Visit.

          4. Item Number Two of the Sexual Interest and Desire Inventory - Female© (SIDI-F©) must
             be rated as &quot;0&quot; or &quot;1&quot; at the Screen Visit

          5. Patients must be willing to try to have sexual activity (e.g., any act involving
             direct genital stimulation) at least once monthly.

          6. Patients must be willing and able to use an eDiary on a daily basis (e.g., have access
             to a working land line or wireless telephone for daily data transmissions).

          7. At the Baseline Visit, patients must have complied with eDiary use adequately, having
             missing entries for five or less days during the 28-day Screen period.

          8. Patients must be in a stable, monogamous, heterosexual relationship that is secure and
             communicative, for at least 1 year prior to the Screen Visit. The relationship is to
             be with the same partner who is sexually functional, both psychologically and
             physically, and the partner is expected to be physically present (i.e., available for
             sexual activity at some time during a 24 hour day) at least 50% of each month during
             the 4-week Screen period and 24-week efficacy period of the trial.

        Exclusion Criteria:

          1. Patients who have taken any medication noted in Appendix 10.6.1, Part I - List of
             prohibited medications, within 30 days before the Screen Visit; the same medications
             are prohibited throughout participation in the study.

          2. Patients whose sexual function was affected (enhanced or worsened) in the investigator
             opinion by any medication within 30 days before the Screen Visit and anytime prior to
             the Baseline Visit. This must be determined by the investigator judgement after
             performing a detailed review of the patient sexual history and concomitant therapy.

          3. Patients with a history of drug dependence or abuse (including alcohol, as defined in
             DSM IV-TR or in the opinion of the investigator) within the past 1 year

          4. Patients who meet DSM IV-TR criteria for Sexual Aversion Disorder, Substance-Induced
             Sexual Dysfunction, Dyspareunia (not caused by inadequate foreplay stimulation or
             alleviated by lubricants), Vaginismus, Gender Identity Disorder, Paraphilia, or for
             Sexual Dysfunction Due to a General Medical Condition.

          5. Patients who indicate that their sexual partner has organic or psychosexual
             dysfunction that could interfere with a patient response to treatment.

          6. Patients who have entered the peri-menopause stage (menopausal transition) or the post
             menopause stage [i.e., have had hysterectomy (without bilateral oophorectomy),
             bilateral oophorectomy, endometrial ablation (any type), and chemical induced (e.g.,
             chemotherapy)] according to the STRAW criteria.

          7. Patients with a history of MDD within 6 months prior the Screen Visit or a score of 14
             on the Beck Depression Inventory© II, or a history of suicide attempt according to the
             Beck Scale for Suicide Ideation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>511.77.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.43006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wörgl</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Braine-l'Alleud</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vresina</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.35805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blanquefort</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3314A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3314B Cabinet médical</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3314C Cabinet médical</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3312A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3315A Cabinet Médical</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Emilion</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.3311A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szentes</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.39004 Ospedale S. Bambino</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.39001 IRCCS S. Fondazione Maugeri</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.39002 Ospedale Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.39003 Ospedale Sant'Anna</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Helder</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.31002 St Antonius ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zeist</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lillestrøm</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L´Hospitalet del LLobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manresa (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mataró-Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orense</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kungsbacka</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.46009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.46001 Junoenheten/Kvinnohälsan, Kvinnokliniken</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fisherwick, Lichfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Headington, Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Brent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.77.44010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <results_first_submitted>April 2, 2014</results_first_submitted>
  <results_first_submitted_qc>May 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2014</results_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flibanserin 50mg</title>
          <description>50 mg qhs
BIMT 17 BS 50 mg: flibanserin 50 mg</description>
        </group>
        <group group_id="P2">
          <title>Flibanserin 100mg</title>
          <description>100 mg qhs
BIMT 17 BS 100 mg: flibanserin 100mg</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>placebo qhs
placebo: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="316"/>
                <participants group_id="P3" count="318"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="216"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flibanserin 50mg</title>
          <description>50 mg qhs
BIMT 17 BS 50 mg: flibanserin 50 mg</description>
        </group>
        <group group_id="B2">
          <title>Flibanserin 100mg</title>
          <description>100 mg qhs
BIMT 17 BS 100 mg: flibanserin 100mg</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>placebo qhs
placebo: placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="311"/>
            <count group_id="B2" value="316"/>
            <count group_id="B3" value="318"/>
            <count group_id="B4" value="945"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-34 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="148"/>
                    <measurement group_id="B4" value="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35-44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="311"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="318"/>
                    <measurement group_id="B4" value="945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="286"/>
                    <measurement group_id="B4" value="843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary.</title>
        <description>To obtain information on satisfying sexual events (SSEs), a small personal handheld electronic device was to be used by the patients to record such information daily (eDiary). An SSE was recorded when a patient answered “yes” to the eDiary question: “Was the event satisfying for you?”</description>
        <time_frame>baseline to 24 weeks</time_frame>
        <population>Patients who had at least one post-dose on-treatment efficacy assessment were included in the Full Analysis Set (FAS). The FAS was used for primary analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Flibanserin 50mg</title>
            <description>50 mg qhs
BIMT 17 BS 50 mg: flibanserin 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 100mg</title>
            <description>100 mg qhs
BIMT 17 BS 100 mg: flibanserin 100mg</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo qhs
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary.</title>
          <description>To obtain information on satisfying sexual events (SSEs), a small personal handheld electronic device was to be used by the patients to record such information daily (eDiary). An SSE was recorded when a patient answered “yes” to the eDiary question: “Was the event satisfying for you?”</description>
          <population>Patients who had at least one post-dose on-treatment efficacy assessment were included in the Full Analysis Set (FAS). The FAS was used for primary analyses.</population>
          <units>events per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="299"/>
                <count group_id="O3" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="3.7"/>
                    <measurement group_id="O2" value="1.5" spread="4.0"/>
                    <measurement group_id="O3" value="0.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Flibanserin 50mg</title>
          <description>50 mg qhs
BIMT 17 BS 50 mg: flibanserin 50 mg</description>
        </group>
        <group group_id="E2">
          <title>Flibanserin 100mg</title>
          <description>100 mg qhs
BIMT 17 BS 100 mg: flibanserin 100mg</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>placebo qhs
placebo: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="311"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="316"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>gliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>metrorrhagia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="311"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="316"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="143" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="311"/>
                <counts group_id="E2" events="49" subjects_affected="39" subjects_at_risk="316"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="311"/>
                <counts group_id="E2" events="67" subjects_affected="54" subjects_at_risk="316"/>
                <counts group_id="E3" events="36" subjects_affected="33" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="45" subjects_affected="36" subjects_at_risk="311"/>
                <counts group_id="E2" events="35" subjects_affected="30" subjects_at_risk="316"/>
                <counts group_id="E3" events="37" subjects_affected="32" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="91" subjects_affected="49" subjects_at_risk="311"/>
                <counts group_id="E2" events="66" subjects_affected="53" subjects_at_risk="316"/>
                <counts group_id="E3" events="67" subjects_affected="42" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="311"/>
                <counts group_id="E2" events="55" subjects_affected="46" subjects_at_risk="316"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="311"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="316"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scientific Program Director</name_or_title>
      <organization>Sprout Pharmaceuticals</organization>
      <phone>9198820850</phone>
      <email>clinicaltrials@sproutpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

